Product Description
Retatrutide is a synthetic peptide agonist at three receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. Research models demonstrate substantial reductions in body weight and glycemic parameters in obesity and type-2 diabetes investigations, exceeding the effects of dual GIP/GLP-1 agonists. The glucagon component is thought to contribute additional hepatic and energy-expenditure effects.









